Associate Scientist
MRC/UVRI & LSHTM Uganda Research Unit, Uganda
Email: calebgwapa@gmail.com
VALIDATE Role:
Network Associate
Research Keywords:
TB immunology, B cells and antibodies, vaccines
Biography:
My research is in the field of tuberculosis (TB) immunology particularly in the area of antibody-mediated immunity against Mycobacterium tuberculosis, its causative agent. I have been involved in cross-sectional studies to characterize the quality of the antibody response in individuals with TB infection. I am also interested in the development of tools that can be used to predict natural or vaccine induced immunity to TB. My goal is to generate information that is important in the advance of new vaccines against TB, a disease that is responsible for many deaths in Uganda.
Related Websites:
Profile page at MUII
Key Publications:
Biraro IA, Egesa M, Kimuda S, Smith SG, Toulza F, Levin J, Joloba M, Katamba A, Cose S, Dockrell HM, Elliott AM. Effect of isoniazid preventive therapy on immune responses to Mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. BMC Infect Dis. 2015;15(1):438. doi: 10.1186/s12879-015-1201-8.
Biraro IA, Kimuda S, Egesa M, Cose S, Webb EL, Joloba M, Smith SG, Elliott AM, Dockrell HM, Katamba A. The use of interferon gamma inducible protein 10 as a potential biomarker in the diagnosis of latent tuberculosis infection. PLoS One. 2016;11(1):e0146098. doi:10.1371/journal.pone.0146098.
Kimuda SG, Nalwoga A, Levin J, Franken KL, Ottenhoff TH, Elliott AM, Cose S A-BI. Humoral Responses to Rv1733c, Rv0081, Rv1735c, and Rv1737c DosR Regulon-Encoded Proteins of Mycobacterium tuberculosis in Individuals with Latent Tuberculosis Infection. J Immunol Res[Internet]. 2017;2017:8. Available from: https://doi.org/10.1155/2017/1593143
Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G,Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, McShane H, Elliott AM. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open- label trial. PLoS Negl Trop Dis 11(5): e0005440. https://doi.org/10.1371/journal.pntd.0005440